Premium
Use of IIb/IIIa inhibitors in patients with in‐stent restenosis treated with intracoronary γ‐radiation: Integrilin WRIST
Author(s) -
Waksman Ron,
Ajani Andrew E.,
Gruberg Luis,
Pinnow Ellen,
GebreEyesus Afework,
Deible Regina,
Satler Lowell F.,
Pichard Augusto D.,
Torguson Rebecca,
Kent Kenneth M.,
Suddath William,
Lindsay Joseph
Publication year - 2004
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20054
Subject(s) - eptifibatide , medicine , restenosis , myocardial infarction , stent , cardiology , surgery , conventional pci
The Integrilin Washington Radiation for In‐Stent Restenosis Trial (WRIST) aimed to study the impact of IIb/IIIa inhibitors as adjunct therapy to intracoronary radiation therapy (IRT) for patients with in‐stent restenosis (ISR). The impact of GP IIb/IIIa inhibitor (eptifibatide) as adjunct therapy to vascular brachytherapy using 192 Ir emitter was examined in patients with in‐stent restenosis. In the study, 150 patients were assigned to eptifibatide (Integrilin) and 150 patients to heparin only. Clinical composite endpoints at 30 days were similar between the patients treated with and without eptifibatide (4.7% vs. 4.0%; P = 0.78). There was a similarity in the non‐Q‐wave myocardial infarction (MI) rates between the eptifibatide and the control group. Major bleeding was similar in patients treated with and without eptifibatide. Overall, the use of eptifibatide as adjunct therapy for patients with ISR that are treated with IRT did not impact the clinical outcome at 30 days. Catheter Cardiovasc Interv 2004;62:162–166. © 2004 Wiley‐Liss, Inc.